GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer

TAIPEI, , April 19, 2017 /PRNewswire/ -- GNT Biotech & Medicals Co., Ltd., (GNTbm) (TPEx: 7427) has announced that the anticancer drug Chidamide (HBI-8000), an epigenetic regulator developed by Chipscreen Biosciences Ltd., of Shenzhen, China, had received approval from the Taiwan Food and Drug ...